Bellerophon Therapeutics Volcan Bond

BLPHDelisted Stock  USD 0.71  0.01  1.43%   
Bellerophon Therapeutics holds a debt-to-equity ratio of 0.047. With a high degree of financial leverage come high-interest payments, which usually reduce Bellerophon Therapeutics' Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

Bellerophon Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Bellerophon Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Bellerophon Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Bellerophon Therapeutics' stakeholders.
For most companies, including Bellerophon Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Bellerophon Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Bellerophon Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
View Bond Profile
Given the importance of Bellerophon Therapeutics' capital structure, the first step in the capital decision process is for the management of Bellerophon Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Bellerophon Therapeutics to issue bonds at a reasonable cost.
Popular NameBellerophon Therapeutics Volcan Compania Minera
SpecializationBiotechnology
Equity ISIN CodeUS0787713009
Bond Issue ISIN CodeUSP98047AC08
S&P Rating
Others
Maturity Date11th of February 2026
Issuance Date11th of February 2021
Coupon4.375 %
View All Bellerophon Therapeutics Outstanding Bonds

Bellerophon Therapeutics Outstanding Bond Obligations

Understaning Bellerophon Therapeutics Use of Financial Leverage

Understanding the composition and structure of Bellerophon Therapeutics' debt gives an idea of how risky is the capital structure of the business and if it is worth investing in it. The degree of Bellerophon Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.
Please read more on our technical analysis page.

Currently Active Assets on Macroaxis

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Consideration for investing in Bellerophon Pink Sheet

If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.